Medpace (NASDAQ: MEDP) officer to sell 3,400 shares of stock
Medpace Holdings, Inc. (MEDP) officer Kevin M. Brady plans to sell 3,400 shares of common stock, valued at approximately $2.1 million, through a Rule 144 notice. This sale is associated with a stock option exercise, with the shares expected to be sold on NASDAQ around August 20, 2026. The company currently has 27,911,655 shares outstanding, making this planned transaction a small percentage of the total.
Madison Asset Management LLC Invests $128.96 Million in Medpace Holdings, Inc. $MEDP
Madison Asset Management LLC has acquired a new stake in Medpace Holdings, Inc. (NASDAQ:MEDP), purchasing 243,502 shares valued at approximately $128.96 million. This investment makes Medpace the 16th largest position in Madison Asset Management's portfolio, representing 1.5% of its total investments. Medpace recently reported strong quarterly earnings, surpassing analyst estimates with EPS of $4.25 and a 17.2% year-over-year revenue increase to $707.33 million.
NewEdge Wealth LLC Invests $27.51 Million in Medpace Holdings, Inc. $MEDP
NewEdge Wealth LLC has acquired a new position in Medpace Holdings, Inc. (NASDAQ:MEDP), purchasing 51,943 shares valued at approximately $27.51 million during the second quarter. This investment makes NewEdge Wealth LLC an approximate 0.19% owner of Medpace. The article also details other institutional investor activity, insider stock sales, recent analyst rating changes, and Medpace's financial performance.
Medpace (NASDAQ: MEDP) director plans $3.0M stock sale
Medpace Holdings, Inc. (NASDAQ: MEDP) director Brian T. Carley plans to sell 5,000 shares of common stock, valued at approximately $3.0 million, on or about August 19, 2026. The shares were acquired through restricted stock vesting and stock option exercises in 2023. This transaction is being facilitated through Fidelity Brokerage Services LLC under Rule 144.
Medpace (NASDAQ: MEDP) director lines up 7,283-share Rule 144 sale
Medpace Holdings, Inc. (NASDAQ: MEDP) director Fred B. Davenport Jr. has filed a Rule 144 notice for the proposed sale of 7,283 shares of common stock. This sale is associated with a stock option exercise dated August 19, 2026, and will be executed through Fidelity Brokerage Services LLC. The filing indicates a neutral impact and sentiment regarding the transaction.
Oxbow Advisors LLC Purchases New Stake in Medpace Holdings, Inc. $MEDP
Oxbow Advisors LLC has acquired a new stake of 9,208 shares in Medpace Holdings, Inc. (NASDAQ:MEDP) valued at approximately $4.9 million during the second quarter. Despite significant institutional ownership (77.98%), analysts maintain a "Hold" rating with an average price target of $584.18, although some firms have raised targets to $665. The company recently surpassed quarterly expectations with $4.25 EPS and $707.33 million in revenue, while insiders have sold nearly $38 million in stock over the past 90 days.
Pallas Capital Advisors LLC Invests $1.13 Million in Medpace Holdings, Inc. $MEDP
Pallas Capital Advisors LLC has acquired a new stake of 2,142 shares, valued at $1.13 million, in Medpace Holdings, Inc. during the second quarter. Other institutional investors have also adjusted their holdings in Medpace, which now has 77.98% institutional ownership. Insider selling has also occurred, with executives selling shares totaling over $4.7 million in recent transactions.
Summit Creek Advisors LLC Invests $3.42 Million in Medpace Holdings, Inc. $MEDP
Summit Creek Advisors LLC recently acquired a new position in Medpace Holdings, Inc. (NASDAQ:MEDP), purchasing 6,449 shares valued at approximately $3.42 million during the second quarter. Other institutional investors also adjusted their stakes in Medpace, with 77.98% of the stock now owned by institutional investors. The company reported strong quarterly earnings, surpassing analyst estimates, and has seen recent insider selling activity, while analysts maintain a "Hold" rating with a consensus price target of $584.18.
Diversify Advisory Services LLC Invests $2.96 Million in Medpace Holdings, Inc. $MEDP
Diversify Advisory Services LLC has acquired a new position in Medpace Holdings, Inc. (NASDAQ:MEDP), purchasing 5,016 shares valued at approximately $2.96 million during the second quarter. This move is part of broader institutional investment activity, with several other firms also adjusting their stakes in Medpace. The article also highlights recent insider selling by Medpace executives and provides an overview of the company's financial performance and analyst ratings.
Medpace (MEDP) Stock May Be 9% Undervalued As Growth Expectations Hold
Medpace Holdings (MEDP) has shown a 233.1% return over five years, leading to a complex valuation. While a Discounted Cash Flow (DCF) model suggests the stock is approximately 9% undervalued, traditional market multiples like the P/E ratio indicate it might be expensive. This mixed valuation means current prices reflect strong growth expectations, and investors need to closely monitor future earnings trajectories to justify the premium.
Medpace Holdings (MEDP) Following Its Q2 Beat And Guidance Raise Looks Fully Valued
Medpace Holdings (MEDP) has seen strong share price momentum recently, driven by a Q2 earnings beat and raised full-year guidance. However, despite this positive performance, a popular narrative suggests the stock is overvalued by 26.9% with a fair value of $456.00, citing concerns about the sustainability of revenue growth and client funding fragility. The article encourages investors to analyze underlying data and risks before making investment decisions, noting the P/E ratio is below peers but above a calculated fair ratio.
HBK Sorce Advisory LLC Invests $2.53 Million in Medpace Holdings, Inc. $MEDP
HBK Sorce Advisory LLC has invested $2.53 million in Medpace Holdings, Inc. (NASDAQ:MEDP) by purchasing 4,309 shares during the second quarter. This move comes as Medpace exceeded its quarterly earnings and revenue expectations, despite insiders selling approximately $38.0 million worth of stock in the past 90 days. Analysts currently maintain a "Hold" rating on MEDP with an average price target of $584.18.
Medpace Holdings, Inc. (MEDP) Stock Analysis: Navigating Growth with a Strong 162.15% Return on Equity
Medpace Holdings, Inc. (MEDP), a key player in the Healthcare Diagnostics & Research industry, demonstrates robust financial health with a 162.15% Return on Equity and 17.20% revenue growth, leading to a strong financial footing. Despite a "hold" consensus from analysts, technical indicators suggest a bullish trend, positioning the company for continued relevance in the growing demand for advanced medical research. Its strategic global presence and comprehensive service offerings make it an attractive long-term investment option.
Focus Partners Advisor Solutions LLC Acquires Shares of 3,182 Medpace Holdings, Inc. $MEDP
Focus Partners Advisor Solutions LLC has acquired a new position of 3,182 shares in Medpace Holdings, Inc. (NASDAQ:MEDP), valued at approximately $1.685 million. Institutional investors collectively own 77.98% of Medpace, which recently reported strong quarterly results with EPS of $4.25 and revenue of $707.33 million, surpassing analyst expectations. The company provided a positive fiscal 2026 EPS guidance, though analysts maintain a consensus "Hold" rating with an average price target of $584.18, and recent insider sales have also been noted.
Medpace CEO August J. Troendle sells $7.1m in company stock
Medpace Holdings Inc. CEO August J. Troendle recently sold approximately $7.1 million worth of company stock over two days in August, despite the shares surging 36% in the past six months. InvestingPro analysis suggests the stock is currently overvalued. This insider sale follows Medpace's strong second-quarter 2026 financial results, which surpassed Wall Street expectations, leading to updated price targets from BMO Capital and TD Cowen.
Local Pensions Partnership Investment Ltd Buys 4,000 Shares of Medpace Holdings, Inc. $MEDP
Local Pensions Partnership Investment Ltd increased its stake in Medpace Holdings, Inc. (NASDAQ:MEDP) by 10.5%, acquiring an additional 4,000 shares to bring its total to 42,000 shares valued at $22.3 million. Despite cautious analyst sentiment and significant insider selling, Medpace exceeded its quarterly earnings and revenue expectations, driven by 17.2% year-over-year revenue growth. Institutional investors now own 77.98% of the company.
Medpace CEO August J. Troendle sells $7.1m in company stock
Medpace Holdings Inc. CEO August J. Troendle recently sold approximately $7.1 million worth of company stock over two days in August. These sales occurred after Medpace shares surged 36% in six months, though an InvestingPro analysis suggests the stock is currently overvalued. The company also reported strong Q2 2026 financial results, exceeding analyst expectations, leading to updated price targets from BMO Capital and TD Cowen.
Medpace (MEDP) CEO August Troendle sells 11,824 shares around $600
Medpace Holdings, Inc. CEO August J. Troendle sold a total of 11,824 shares of common stock over two days in August 2026, with sales occurring at weighted average prices of $601.53 and $600.39 per share. These transactions were executed via limit orders during an open window period. Troendle also indirectly holds over 4.7 million shares through Medpace Investors, LLC.
Medpace CEO August J. Troendle sells $7.1m in company stock
Medpace Holdings CEO August J. Troendle recently sold approximately $7.1 million worth of company stock over two days in August, reducing his direct holdings to 603,978 shares. This insider sale follows a 36% surge in Medpace shares, although InvestingPro analysis indicates the stock may be overvalued. The company reported strong Q2 2026 financial results, exceeding Wall Street expectations, with BMO Capital and TD Cowen raising their price targets based on robust performance and business trends.
T. Rowe Price (MEDP) discloses 7.2% Medpace Holdings stake in latest filing
T. Rowe Price Associates, Inc. has disclosed a 7.2% beneficial ownership stake in Medpace Holdings, Inc. (MEDP) through a SCHEDULE 13G filing. This represents 2,069,679 shares, with T. Rowe Price retaining sole voting power over 2,012,425 shares and sole dispositive power over all 2,069,679 shares. The firm clarifies that this filing should not be construed as an admission of beneficial ownership.
Retirement Systems of Alabama Sells 4,152 Shares of Medpace Holdings, Inc. $MEDP
Retirement Systems of Alabama reduced its stake in Medpace Holdings, Inc. (NASDAQ:MEDP) by 6.6% in the second quarter, selling 4,152 shares but still retaining 59,199 shares valued at approximately $31.4 million. Despite this sale, other institutional investors increased their positions, and Medpace reported strong quarterly results with higher-than-expected EPS and revenue, alongside optimistic fiscal 2026 guidance. The stock currently holds a consensus "Hold" rating from analysts with a target price of $584.18.
Atria Investments Inc Has $1.01 Million Position in Medpace Holdings, Inc. $MEDP
Atria Investments Inc significantly reduced its stake in Medpace Holdings, Inc. (NASDAQ:MEDP) by 66.2% in the second quarter, now holding 1,907 shares valued at approximately $1.01 million. Despite insider sales totaling $30.88 million, Medpace reported strong quarterly earnings of $4.25 per share, exceeding estimates, and anticipates fiscal 2026 earnings between $17.25 and $17.95 per share. Analysts currently maintain a consensus "Hold" rating for the stock with an average price target of $584.18.
Medpace Holdings Inc (MEDP) Director McCarthy Cornelius P. III Sells 1,140 Shares
Medpace Holdings Inc (MEDP) Director McCarthy Cornelius P. III sold 1,140 shares of the company for approximately $690,121.80, continuing a trend of insider selling over the past year. Despite this, the stock is considered "Fairly Valued" by GuruFocus's GF Value, and prominent investment gurus are largely maintaining or increasing their positions. Investors are advised to consider the broader context of the company's strong fundamentals and growth prospects alongside the insider activity.
Medpace Holdings (MEDP) director McCarthy sells 1,140 shares at $605.37
Medpace Holdings, Inc. director Cornelius P. McCarthy III sold 1,140 shares of common stock on August 11, 2026, at a price of $605.37 per share, totaling approximately $690,000. This transaction was an open market sale and was not conducted under a Rule 10b5-1 trading plan. Following the sale, McCarthy's direct holdings in the company amount to 12,275 shares.
Medpace Holdings Insider Sold Shares Worth $690,122, According to a Recent SEC Filing
An insider at Medpace Holdings sold shares valued at $690,122, as disclosed in a recent SEC filing. This transaction follows another insider sale of $4.5 million in shares reported on July 29th. Medpace Holdings, a clinical contract research organization, has seen recent analyst price target increases and a jump in stock price following a Q2 earnings beat and order rebound.
Annex Advisory Services LLC Has $1.56 Million Stock Holdings in Medpace Holdings, Inc. $MEDP
Annex Advisory Services LLC significantly reduced its stake in Medpace Holdings, Inc. (NASDAQ:MEDP) by 96.9% in the second quarter, now holding 2,943 shares valued at approximately $1.56 million. Despite this, Medpace reported a strong quarterly earnings beat with EPS of $4.25 and revenue of $707.33 million, a 17.2% increase year-over-year. Analysts generally maintain a "Hold" rating on the stock, while company insiders have sold a substantial amount of shares recently.
Medpace Holdings (MEDP) CEO sells 23,144 shares, reports 4.73M held via LLC
Medpace Holdings, Inc. President & CEO August J. Troendle sold a total of 23,144 shares of Medpace common stock on August 10 and 11, 2026, for approximately $13.98 million. The sales were executed through limit orders during an open window period. Troendle also reported indirect ownership of 4,733,019 shares through Medpace Investors, LLC, where he is the sole manager with voting and investment control, though he disclaims beneficial ownership beyond his pecuniary interest.
Here's How Much a $1000 Investment in Medpace Made 10 Years Ago Would Be Worth Today
This article analyzes the hypothetical return on a $1000 investment in Medpace (MEDP) made ten years ago, calculating its current value to be $21,788.41, representing a 2,078.84% gain. It also provides an in-depth look at Medpace's business operations, financial performance, and future outlook, noting analyst expectations for continued upside despite some potential challenges.
Medpace Holdings, Inc. $MEDP is Wasatch Advisors LP's 5th Largest Position
Wasatch Advisors LP has reduced its stake in Medpace Holdings, Inc. (MEDP) by 17.7%, but it still remains their fifth-largest holding, representing 2.2% of their portfolio. Despite the firm's strong quarterly earnings, analysts maintain a cautious "Hold" rating with an average price target below the current stock price, and insiders have sold over $16.2 million in shares. Medpace reported robust Q2 earnings with EPS of $4.25, exceeding estimates, and revenue growth of 17.2%.
Medpace director McCarthy sells $465,131 in company shares
Medpace Holdings director Cornelius P. McCarthy III sold 795 shares of company stock for $465,131 after exercising options to acquire 3,858 shares. Following these transactions, McCarthy directly holds 13,415 shares. The sale comes as Medpace reported strong Q2 2026 financial results, exceeding Wall Street expectations, with BMO Capital and TD Cowen raising their price targets, although the stock is noted to appear overvalued by InvestingPro.
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Medpace Holdings, Inc. (MEDP) And Encourages Shareholders to Reach Out
Bronstein, Gewirtz & Grossman, LLC has initiated an investigation into potential corporate wrongdoing by Medpace Holdings, Inc. (NASDAQ:MEDP) and certain of its officers and/or directors. The firm is encouraging shareholders who purchased Medpace securities prior to April 22, 2025, and still hold them, to come forward and assist in the investigation. They operate on a contingency fee basis, aiming to restore investor capital and ensure corporate accountability.
Medpace (MEDP) director exercises 3,858 options and sells 795 common shares
Medpace Holdings, Inc. director Cornelius P. McCarthy III exercised options for 3,858 shares of common stock at $84.36 per share on August 7, 2026, and subsequently sold 795 of these shares at $585.071 per share. The exercised option had vested in 2021 and was set to expire in 2027. This transaction represents a net sale of 795 shares, and the Rule 10b5-1 checkbox was not marked, indicating it was not part of a pre-planned trading arrangement.
Assenagon Asset Management S.A. Sells 90,551 Shares of Medpace Holdings, Inc. $MEDP
Assenagon Asset Management S.A. significantly reduced its stake in Medpace Holdings, Inc. by selling 90,551 shares, leaving it with 25,772 shares valued at $13.65 million. Despite this, Medpace exceeded Q2 earnings expectations with $4.25 EPS and $707.33 million in revenue, and issued strong fiscal 2026 EPS guidance. Analysts generally maintain a "Hold" rating on the stock, while company insiders have also been selling shares.
Medpace Holdings faces lawsuit over alleged misleading growth info causing inflated stock prices.
Medpace Holdings Inc. is being investigated by Kuehn Law for allegedly misleading shareholders with misrepresented business metrics, including backlog cancellations and growth projections. The lawsuit claims these overly optimistic expectations led investors to purchase stock at inflated prices. Shareholders who bought stock before April 22, 2025, are urged to contact Kuehn Law to enforce their rights, highlighting the risks of inaccurate corporate disclosures on investor decisions and stock valuations.
Kuehn Law Encourages Investors of Medpace Holdings, Inc. to Contact Law Firm
Kuehn Law, PLLC is investigating Medpace Holdings, Inc. (NASDAQ: MEDP) for potential breaches of fiduciary duties by its officers and directors. A federal securities lawsuit alleges that Medpace misrepresented its backlog cancellation rates, business conditions, and ability to maintain its projected 1.15 book-to-bill ratio, leading to artificially inflated stock prices. The firm encourages investors who purchased MEDP prior to April 22, 2025, to contact them to discuss their rights.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Medpace Holdings, Inc. (MEDP) and Encourages Shareholders to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Medpace Holdings, Inc. (MEDP) regarding potential corporate wrongdoing by its officers and/or directors. The firm encourages shareholders who purchased Medpace securities before April 22, 2025, and continue to hold them, to join the investigation. Bronstein, Gewirtz & Grossman, LLC operates on a contingency fee basis, aiming to restore investor capital and ensure corporate accountability.
Should Medpace’s (MEDP) Golden Cross and Upgraded Estimates Prompt a Fresh Look at Its Valuation?
Medpace Holdings (MEDP) recently experienced a "golden cross" and upward revisions to earnings estimates, indicating technical momentum and improved financial expectations. The article examines how these factors interact with the company's investment narrative, focusing on its ability to convert backlog into revenue while managing costs and client concentration risk. Despite an increased full-year guidance for 2026, the company's valuation still suggests a potential downside to its current price according to Simply Wall St's fair value estimate.
Should Medpace’s (MEDP) Golden Cross and Upgraded Estimates Prompt a Fresh Look at Its Valuation?
Medpace Holdings (MEDP) recently experienced a "golden cross" and received upgraded earnings estimates, suggesting positive technical momentum and improved financial prospects. While these developments highlight stronger near-term performance and reinforce the company's backlog conversion, investors should consider the risk of concentrated client exposure and the sustainability of current growth and margin levels. Despite these positive indicators, Medpace's projected fair value suggests a potential downside to its current price.
Medpace Holdings, Inc. (MEDP) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Medpace Holdings, Inc. (NASDAQ: MEDP) concerning potential corporate wrongdoing by its officers and/or directors. The firm is encouraging investors who purchased Medpace securities before April 22, 2025, and still hold them, to contact them to assist with the investigation. This investigation aims to restore investor capital and ensure corporate accountability.
Medpace Holdings, Inc. SEC Filing (Aug 7, 2026)
This article reports on Medpace Holdings, Inc.'s SEC Form 144 filing on August 7, 2026, detailing a proposed sale of securities. The filing indicates the sale of 795 shares of common stock acquired through stock option exercise on the same date, with an aggregate market value of $465,131.45. The article also provides Medpace's stock data, rankings, and recent news and SEC filings.
Should You Investigate Medpace Holdings, Inc. (NASDAQ:MEDP) At US$585?
The article discusses whether Medpace Holdings, Inc. (NASDAQ:MEDP) is a good investment at its current share price of US$585. It delves into the company's valuation, considering factors such as its price-to-earnings (P/E) ratio and future growth prospects. The analysis aims to help potential investors determine if Medpace is trading at a fair value or if there's an opportunity for upside.
Medpace Holdings Inc (MEDP) Stock News Today
This page provides news and analysis for Medpace Holdings Inc (MEDP). It highlights the company's stock performance, including a recent surge after strong earnings, and offers various financial and analytical tools for investors. The article mentions a significant event where Medpace's strong earnings caused its shares to surge by 54%.
Medpace Holdings, Inc. $MEDP Shares Sold by The Manufacturers Life Insurance Company
The Manufacturers Life Insurance Company reduced its stake in Medpace Holdings, Inc. ($MEDP) by 12.5% in the first quarter, selling 2,063 shares. Despite this, Medpace reported strong quarterly results with higher-than-expected EPS and revenue, and issued positive fiscal 2026 EPS guidance. The stock opened at $587.75, with analysts maintaining a "Hold" rating and an average price target of $584.18, while company insiders have recently sold shares worth $16.2 million.
Is MEDP Worth Buying as Growth Collides With a Premium Valuation?
Medpace Holdings, Inc. (MEDP) exhibits compelling growth with double-digit earnings, strong profitability, and improving bookings, along with a significant pipeline for 2027. However, its valuation is considerably higher than industry and market averages. While the company's operational quality is high, the premium valuation and potential for uneven booking visibility suggest a selective approach rather than aggressive buying.
Bronstein, Gewirtz & Grossman, LLC Encourages Medpace Holdings, Inc. (MEDP) Shareholders to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Medpace Holdings, Inc. (NASDAQ:MEDP) securities. The investigation concerns whether Medpace and its officers/directors engaged in corporate wrongdoing, particularly for investors who purchased shares before April 22, 2025, and still hold them. The firm encourages affected shareholders to contact them for more information and to assist in the investigation at no cost, as they operate on a contingency fee basis.
Pacer Advisors Inc. Sells 107,271 Shares of Medpace Holdings, Inc. $MEDP
Pacer Advisors Inc. significantly reduced its stake in Medpace Holdings, Inc. (NASDAQ:MEDP) during the first quarter of 2026, selling 107,271 shares and retaining 46,381 shares valued at approximately $22.3 million. Despite this reduction, other institutional investors have increased their holdings, and the company reported strong Q1 earnings, beating analyst estimates with EPS of $4.25 and a 17.2% year-over-year revenue increase. Analyst sentiment remains cautious with a "Hold" rating, while company insiders have also sold a substantial number of shares recently.
Amundi Buys 57,288 Shares of Medpace Holdings, Inc. $MEDP
Amundi increased its stake in Medpace Holdings, Inc. (MEDP) by 1,487.6% in the first quarter, acquiring 57,288 additional shares and bringing its total holdings to 61,139 shares valued at $29.4 million. Despite institutional ownership of 77.98% and strong quarterly earnings, analysts maintain a "Hold" rating, while company insiders have sold over 31,000 shares worth $16.2 million in the last three months. Medpace reported an EPS of $4.25 and revenue of $707.33 million, surpassing consensus estimates, and issued a positive fiscal 2026 EPS guidance.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Medpace Holdings, Inc. (MEDP) And Encourages Investors to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Medpace Holdings, Inc. (NASDAQ:MEDP) who bought securities prior to April 22, 2025, and still hold them. The investigation aims to determine if Medpace and its officers engaged in corporate wrongdoing. The firm encourages affected investors to contact them for more information, offering their services on a contingency fee basis.
Have Medpace Holdings Insiders Been Selling Stock?
Medpace Holdings (NASDAQ: MEDP) insiders have been selling stock, with the CEO selling $62 million worth and another insider selling $4.5 million recently. While insider ownership remains significant at 20% ($3.2 billion), the lack of insider buying and recent sales at current price levels raise some caution, despite the company being profitable and growing.
Have Medpace Holdings Insiders Been Selling Stock?
Recent insider transactions at Medpace Holdings, Inc. revealed that an insider sold US$4.5 million worth of shares, reducing their holding by 11%. Over the last year, the CEO also sold US$62 million worth of shares at a price close to the current share price. While there have been no insider purchases, the company maintains high insider ownership and is profitable and growing.
